A nano-disperse ferritin-core mimetic that efficiently corrects anemia without luminal iron redox activity. by Powell, JJ et al.
	



	
	
	
	

	
				
 

!
∀##∀∃%%&∀∋(∀(∀)∀!

	∀∗∀+

∀)∀!,

∀#∀
	−.∀/∀∋0
∀#∀∃
∀1!!∀.2345671
−
	−
00				,
	0	
	0

8		,
)
0)
	

%,∀∃

%,9∀65376:4;−6: 2∋∋)
6:;−;<4
		8

%65656<=
456 64566

		
		

	
	>	

				

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13 Abstract
14 The 2-5 nm Fe(III) oxo-hydroxide core of ferritin is less ordered and readily bioavailable compared to its pure synthetic analogue,
15 ferrihydrite. We report the facile synthesis of tartrate-modified, nano-disperse ferrihydrite of small primary particle size, but with enlarged or
16 strained lattice structure (~2.7 Å for the main Bragg peak versus 2.6 Å for synthetic ferrihydrite). Analysis indicated that co-precipitation
17 conditions can be achieved for tartrate inclusion into the developing ferrihydrite particles, retarding both growth and crystallization and
18 favoring stabilization of the cross-linked polymeric structure. In murine models, gastrointestinal uptake was independent of luminal Fe(III)
19 reduction to Fe(II) and, yet, absorption was equivalent to that of ferrous sulphate, efficiently correcting the induced anemia. This process may
20 model dietary Fe(III) absorption and potentially provide a side effect-free form of cheap supplemental iron.
21 Crown Copyright © 2013 Published by Elsevier Inc. All rights reserved.
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23
24 IntroducQ3 tion
25 Despite all attempts to eradicate or even reduce iron
26 deficiency anemia (IDA), it remains the most prevalent
27nutritional deficiency disorder in the world affecting around 1
28billion people, of which nearly 400 million are children.1 In
29childhood, IDA is associated with increased morbidity and
30reduced cognitive development and IDA remains on the World
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31 Health Organisation (WHO) “top ten” hit list of targeted global
32 health problems.2-4
33 Unlike most nutritional deficiencies, IDA is not confined
34 to underdeveloped and developing countries: in the UK,
35 for example, IDA affects around 5% of adults, nearly 12%
36 of pre-school children and, in some areas, up to 25% of
37 school children.1,5,6
38 To help combat IDA, oral iron supplementation needs to be
39 well tolerated, cheap, safe and effective but current preparations
40 fail in at least one of these criteria. Simple ferrous iron [Fe(II)]
41 salts are most commonly used as these are inexpensive and the
42 iron is well absorbed. However, they have lately come under the
43 spotlight in high-profile intervention trials as they may enhance
44 systemic infection rates, induce undesirable changes to com-
45 mensal bacteria of the colon and increase pro-inflammatory
46 signaling of the gut epithelium.7-10 Some forms of ferric iron
47 [Fe(III)] (e.g. ferric pyrophosphate) are considered safer and
48 better tolerated in the gut lumen than Fe(II) but are poorly
49 absorbed.11-14 Chelation may overcome the issue of oral Fe(III)
50 bioavailability but then marked enhancement of colon cancer
51 risk is seen in rodent models using chelates of Fe(III) EDTA15 or
52 Fe(III) citrate16 for example. In pursuit of strategies for optimal
53 oral Fe supplementation we considered the chemical speciation
54 of dietary Fe(III) and its processing in the gastrointestinal tract.
55 In this respect, carefully designed studies have shown that Fe(III)
56 is well absorbed from ferritin.17-19 Ferritin is the broadly
57 conserved biological storage form of iron and, thus, is found in
58 both meat- and plant-based foods of the human diet: it is
59 composed of a protein shell with a ferrihydrite-like mineral
60 core.20,21 Ferrihydrite is a poly oxo-hydroxide Fe(III) nanopar-
61 ticle (about 2- to 5-nm diameter) with a precise atomic structure
62 that still remains a matter of debate because its size and
63 crystallographically defective nature make its definitive charac-
64 terization challenging.22-27 Notably, in ferritin, the surface of the
65 ferrihydrite-like core appears destabilized (i.e. amorphous)
66 compared to synthetic or geological ferrihydrite20 which must
67 be related to interactions between the ferritin protein shell and the
68 ferrihydrite surface and may involve a phosphate-rich surface
69 layer.28 Indeed the morphology of the ferritin mineral core has
70 been shown to follow the symmetry of the protein shell.20,29
71 Such surface destabilization probably ensures that iron in ferritin
72 is abnormally labile for an oxo-hydroxide in the presence of
73 protons or ligands: thus it is rapidly turned over in the cell
74 lysosome and will solubilize in gastric acid.17,30-32 However, it is
75 a matter of debate as to whether the protein shell and ferrihydrite-
76 like core of ferritin control the slow release of Fe(III) ions from
77 the gastric environment, or, if ferritin as a whole or as a protein-
78 denuded mineral nanoparticle is rapidly emptied from the
79 stomach and endocytosed by the intestinal epithelial cell and
80 broken down intra-lysosomally.18,32,33 Either way ferritin is an
81 effective, bioavailable form of dietary iron that has, for example,
82 led to considerable investment by the Global HarvestPlus
83 Initiative in “bio-fortification” which involves the selection of
84 staple food crops with enriched ferritin expression.34-37
85 Iron supplementation with pure ferritin would be immensely
86 challenging due to the required scale of purification or the
87 complexity of in vitro synthesis, and thus overall costs.
88 However, synthetically, it may not be necessary to exactly
89mimic the ferritin molecule. When organic molecules are present
90during the pH-induced formation of aquated ferrihydrite they can
91do more than simply adsorb to the surface of freshly precipitated
92ferrihydrite. Ligands, such as low-molecular-weight organic
93acids, may abate the degree of iron–oxygen and hydroxyl
94octahedra linking, diminishing the primary particle size and
95retarding maturation and crystallization of the cross-linked
96polymer of freshly precipitated ferrihydrite.38,39 We show here
97that simple aqueous conditions can be identified that allow small
98hydroxyl–carboxyl organic ligands to be co-precipitated with
99freshly forming ferrihydrite such that the ligand markedly
100disrupts ferrihydrite stability and, that in this fashion, bioavail-
101able ferritin-core functional-mimetics were readily synthesised.
102For downstream applications (i.e. affordable supplementation)
103we focussed on cheap, generally recognized as safe (GRAS)
104dietary ligands to provide the modifications and we concentrated
105on nano-dispersion and enhanced rates of acid dissolution as
106initial desirable properties in light of current knowledge on
107dietary ferritin as an oral iron source.
108Methods
109Synthesis of solid ferrihydrite materials
110The ligand-modified ferrihydrite materials were produced by
111co-precipitation and ligand substitution of oxo/hydroxy groups
112following the protocol described by Powell et al.38 Briefly, an
113acidic concentrated stock solution of Fe(III) chloride was added
114to a solution containing the ligand, buffer and 0.9% (wt/vol) of
115electrolyte (sodium chloride; NaCl) or, in the case of synthetic
116ferrihydrite, simply 0.9% NaCl. The initial pH of the mixture was
117always below 2.0, and the iron was fully solubilized. The pH was
118then slowly increased by drop-wise addition of a concentrated
119solution of NaOH with constant agitation until reaching the
120desired final pH (ca. 7.4 for ligand-modified ferrihydrite and 7.4-
1218.2 for synthetic ferrihydrite). In the case of synthetic ferrihydrite
122the entire mixture was then oven dried at 45 °C for a minimum of
12324 h. For the ligand-modified ferrihydrite materials, ultrafiltra-
124tion (3,000 Da MWCO, Vivaspin®) followed by one H2OUHP
125wash was used to remove excess soluble ligand and buffer, i.e.
126non-bound or non-adsorbed to the nanoparticles (≥95%
127recovery according to the manufacturer's specifications), before
128the material was oven dried (again 45 °C) for at least 24 h.
129Physicochemical characterization
130Iron content and phase distribution
131Total iron content was determined by inductively coupled
132plasma optical emission spectrometry (ICP-OES JY 2000,
133Horiba Jobin Yvon Ltd., Stanmore, UK). ICP-OES standards
134and samples were diluted in 5% HNO3 to concentrations in the
135range 0-1000 ppm. Fractionation of the Fe into percentages of
136precipitated, nanoparticulate, and soluble Fe, for each of the Fe
137materials was achieved by centrifugation and ultrafiltration.
138Aqueous suspensions were centrifuged (10,000 × g, 5 min) and
139the sediment taken to be the precipitated fraction. In order to
140isolate the soluble Fe, and to distinguish it from disperse or
141colloidal (i.e. nanoparticulate) Fe, the supernatant was ultra-
142filtered (3,000 Da MWCO; 10,000 × g, 10 min). The Fe content
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143 of all fractions (total, supernatant and ultrafiltrate) was
144 determined by ICP-OES and expressed as percentage ± SD in
145 relation to total Fe content as follows:
%ð Þ Fe precipitated½  ¼ Total Fe–Fesupernatant
 
=Total Fe
 
 100
1467
%ð Þ Fe nanoparticulate½  ¼ Fesupernatant–Feultrafiltrate
 
=Total Fe
 
 100
1489
%ð Þ Fe soluble½  ¼ Feultrafiltrateð Þ=Total Fe½   100
1501 The iron materials were further characterized in terms of
152 particle morphology by high-angle annular dark-field aberration-
153 corrected scanning transmission electron microscopy (HAADF-
154 STEM), X-ray diffraction, Fourier transform infrared spectroscopy
155 (FTIR), electron energy-loss spectroscopy (EELS) and acid
156 dissolution profiles. These methods are detailed in Supplementary
157 Materials.
158 Animal studies
159 Six-week-old male mice, CD1 strain (Charles Rivers, Kent,
160 UK), were used for the “ferrozine” study. Mice were housed in
161 a light- and temperature-controlled room with ad libitum access
162 to standard pellet diet and water. Animal care and the regulation
163 of scientific procedures met the criteria laid down by the
164 United Kingdom Animals (Scientific Procedures) Act 1986.
165 Iron deficiency was induced by feeding 3- to 4-week-old mice a
166 purified low-iron diet (Harlan Teklad, USA) with less than
167 1 mg Fe/kg for at least 2 weeks. Iron absorption studies were
168 performed on iron-deficient mice fasted for ca. 16 h prior to the
169 oral Fe dose. The Fe materials were prepared as described
170 above at 20 mM Fe, labeled with 59Fe (ca. 3.1 MBq) at the time
171 of synthesis (intrinsic labeling), and administered by oral
172 gavage directly into the stomach as a single 100-μl dosage.
173 Two oral doses of 10 mM ferrozine40 or water (control) were
174 given 1 h prior to and during the gavage with the Fe
175 compounds. Mice were left for 4 h with free access to drinking
176 water until sacrifice and tissue collection. The stomach, small
177 intestine and cecum plus colon were removed. The duodenum
178 was removed and rinsed with 0.15 M NaCl. Intestinal tissue
179 samples and duodenal washings were counted for 59Fe using a
180 LKB Wallac gamma counter. The carcass was counted for 59Fe
181 in a small animal whole body gamma counter (LIVE-1,
182 Technical Associates, Canoga Park, CA). Standards were also
183 measured in both counters to correct for the difference in
184 sensitivity. Mucosal transfer was the amount of 59Fe in the
185 carcass expressed as a percentage of administered dose: i.e.
186 the amount of 59Fe radioactivity in the carcass 4 h after the
187 gavage and is expressed as percentage of the total amount
188 of radioactivity that is emptied out of the stomach. The soluble
189 ferric iron control was Fe(III) nitrilotriacetate complex (i.e.
190 Fe(III) NTA).
191 The bioavailability study in rats was conducted by MPI
192 Research (Michigan, USA) and was approved by the Institu-
193 tional Animal Care and Use Committee (IACUC) (MPI study
194 protocol number 1925-001) following United States Animal
195 Welfare Regulations. Hemoglobin was measured by clinical
196pathology as part of a complete blood count (CBC) panel.
197The increase in hemoglobin at day 14 was used as a measure
198of the bioavailability of the ligand-modified ferrihydrite
199in comparison with synthetic ferrihydrite and the current
200gold standard for iron supplementation (Fe(II) sulphate). Male
201Sprague–Dawley [Crl:CD® (SD)] rats (n = 32) were approx-
202imately 21 days old at arrival (Charles River Laboratories).
203The animals were housed individually in polyboxes with toys
204and fed Block Lab Diet® Certified Rodent Diet #5002
205(PMI Nutrition International, Inc), ad libitum during the
206acclimation period (not less than 7 days). The control diet,
207i.e. the iron-deficient (ID) diet (AIN-93G Purified Rodent Diet,
208Dyets Inc., PA, USA) was administered to all animals from day
2090 to day 24 (for the complete diet composition see
210Supplementary Table 2). The incorporation of the iron
211materials into the diets (~30 mg Fe/kgdiet) and pelletization
212through extrusion were carried out by Dyets Inc. Other than the
213varying Fe compound, the diets were equivalent and conformed
214to AIN-93G-purified rodent diet.41
215Administration of the test diets, ID diet fortified with Fe(II)
216sulphate, ID diet fortified with synthetic ferrihydrite, and ID
217diet fortified with tartrate-modified ferrihydrite, began on day
21825. Three groups of eight male rats each were administered
219the test diets. One additional group of eight animals served as
220the no-iron control and continued to receive the un-
221supplemented ID diet. The test and control diets were
222administered for 14 days (i.e. until day 38). Rats consumed
223tap water and the control or test diets ad libitum throughout
224the study. Body weights were measured and recorded weekly.
225Blood samples for clinical chemistry evaluations were
226collected on days −1, 25, and 39. After the study termination
227(day 39) the rats were anaesthetized by CO2 inhalation and
228animals were euthanized by exsanguination.
229Results
230Iron material characterization
231With initial screening in vitro we sought common GRAS
232(or “biologically safe”) ligands that would enable the formation
233of nano-dispersed, rather than aggregated or agglomerated,
234ferrihydrite materials upon titration of an acidic Fe(III)/ligand
235solution with base.
236To ensure repeatability we used two separate buffers in
237parallel, namely adipate and tryptophan. Consistently, 40 mM
238Fe(III) and sub-equimolar tartrate yielded nano-dispersed Fe
239oxo-hydroxide materials: for optimal yield of the nano-
240disperse material the Fe(III)/tartrate ratio was 2:1 and pH
241buffered to greater than 7.0 (≥90% yield: open triangles,
242Figure 1, A and Supplementary Figure S1A). Buffer alone
243(adipate or tryptophan) had no effect and Fe(III) oxo-
244hydroxide aggregation and precipitation preceded as normal
245(closed circles, Figure 1, A and Supplementary Figure S1A).
246We aimed to obtain dry materials that would re-disperse once
247aquated at the appropriate pH so, we next confirmed that,
248when re-introduced into the original volume of aqueous
249solution, the material again was nano-dispersed or precipitat-
250ed according to pH in line with the original titration profile
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251(open triangles, Figure 1, B and Supplementary Figure S1B).
252To determine whether acid-driven dissolution was enhanced
253with tartrate modification we followed iron solubility in HCl
254at pH 1, as recently undertaken by Hilty et al.42 as a proxy
255for Fe(III) bioavailability following oral dosing. The tartrate-
256modified ferrihydrite showed markedly greater solubility than
257similarly prepared ferrihydrite precipitated in the absence of
258tartrate (Figure 1, C and Supplementary Figure S1C).
259To determine whether nano-dispersion alone or modification
260of the ferrihydrite primary particles (i.e. modification of
261synthetic ferrihydrite) had occurred during co-precipitation
262with tartrate, we used powder X-ray diffraction (XRD),
263analytical electron microscopy and Fourier transform infrared
264spectroscopy (FTIR). Initial identification of synthetic ferrihy-
265drite (i.e. the dried control material without ligand modification)
266was performed using powder XRD (Figure 2): Two broad peaks
267were present, centered at ~35° and 62° 2θ (2.6 Å and 1.5 Å
268respectively), and are characteristic of two-line ferrihydrite.43
269Spherical aberration-corrected high-angle annular dark-field
270(HAADF) scanning transmission electron microscopy (STEM)
271imaging (Figure 2) indicated that the average crystallite sizes
272ranged from 2 to 4 nm. This size, and the morphology, were
273exactly as expected for two-line ferrihydrite.24 Contrast in
274HAADF-STEM images is sensitive to atomic number (to the
275power of about 1.7) and spherical aberration correction enables
276atomic contrast to be obtained.20 Thus the image of synthetic
277ferrihydrite (Figure 2, D) emphasizes the lattice positions of the
278iron atoms in this nanocrystalline material (since iron is the
279heaviest element in ferrihydrite).
280Synthesis, as above, in the presence of tartrate (Fe/
281tartrate = 2:1), followed by ultrafiltration (3 kDa MWCO),
282washing and drying, yielded a powder XRD pattern with
283broader, less well-defined Bragg peaks, shifted to 33° and 61°
2842θ respectively (2.7 Å and 1.5 Å; Figure 2). Consistent with
285the qualitative changes in broadening of the XRD pattern,
286corresponding HAADF-STEM images highlighted the notable
287nanoparticle dispersion and a marked decrease in overall
288crystallite order and size (to ca. 1-1.5 nm) of the tartrate-
289modified ferrihydrite (Figure 2, A and B) compared to
290synthetic ferrihydrite (Figure 2, D).
291The infrared spectrum of synthetic ferrihydrite (black line,
292Figure 3) was entirely consistent with that previously
293reported,44,45 whereas that of ferrihydrite precipitated in the
294presence of tartrate (Fe/tartrate = 2:1), and then ultrafiltered,
295washed and dried (red line, Figure 3), showed a mixed profile of
296tartrate (green line, Figure 3) plus ferrihydrite (black line,
297Figure 3) but with no evidence of buffer (tryptophan) which,
298if present, would show strong unique peaks at ~700 and
2993350 cm−1 (blue line, Figure 3): moreover, the tartrate-modified
300ferrihydrite (red line, Figure 3) generated only broad tartrate
301peaks, distinct to those of sodium tartrate (e.g. the sharp doublet
302of ~1100 cm−1; green line, Figure 3). The similarity between the
303infrared spectra for tartrate and adipate (particularly at
304~3000 cm−1) precludes such discriminatory comparisons when
305using the adipate buffer for synthesis.
306Transmission electron microscopy (TEM) with electron
307energy-loss spectroscopy (EELS) was used to probe the local
308iron environments of the ferrihydrite materials (Figure 4). The Fe
Figure 1. Formation of tartrate-modified ferrihydrite in adipate buffer as a function
of pH. (A) Dispersed or colloidal (i.e. nanoparticulate) iron, determined following
centrifugation and ultrafiltration to remove soluble iron (main panel), and
precipitated (i.e. agglomerated) iron, determined following centrifugation (inset).
Closed squares show synthetic ferrihydrite precipitated from an Fe(III) chloride
solution; open triangles show modified ferrihydrite precipitated from an Fe(III)
chloride solution in the presence of sodium tartrate and adipate buffer (Fe/tartrate/
adipate = 1:0.5:0.5); closed circles and open diamonds show ferrihydrite
precipitated from an Fe(III) chloride solution in the presence of adipate alone (Fe/
adipate = 1:0.5 and 1:1 respectively). (B) Percentage of nanoparticulate iron (main
panel) and precipitated iron (inset) for the synthetic (closed squares) and tartrate-
modified (open triangles) ferrihydritematerials (molar ratios as above) re-suspended
in the original volume of aqueous solution. (A andB)All values are expressed as a
percentageof total iron in the initial solution as described inMethods. (C)Simulated
gastric dissolution at pH 1.0 of dried synthetic ferrihydrite (closed squares) and
tartrate-modified ferrihydrite that hadbeen precipitated in the presence of tartrate and
adipate (open triangles), atmolar ratios as above, and then dried.Datawere obtained
following 5-min ultrafiltration (3000 Da MWCO); data are mean ± SD, n = 3.
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309 L2,3-edge spectrum of the synthetic (unmodified) material was
310 again consistent with that of synthetic ferrihydrite27,46,47 while
311 the tartrate-modified ferrihydrite Fe spectrum was almost
312 identical suggesting that the ferrihydrite (or at least the Fe(III))
313 nature of the material was retained (Figure 4). An apparent very
314 minor shift of the Fe L3-peak maxima from 709.5 eV (Fe(III))
315 toward 707.5 eV (Fe(II)) should be viewed with caution as our
316 previous data have shown that even with carefully controlled
317 electron exposure, organic moieties will enhance the suscepti-
318 bility of ferrihydrite to irradiation damage.27,46,47 The same
319 should be noted for the carbon and oxygen K-edges at around
320 285 and 530 eV respectively, although the modified material
321 shows, as expected, a much greater content of the organic-
322 derived signals (Figure 4).
323 Taken together the XRD, STEM, FTIR and EELS data
324 show that the tartrate-modified ferrihydrite is a disrupted or
325 strained ferrihydrite structure where the tartrate ligand has
326 been incorporated into the particles during co-precipitation
327 and we suggest that this leads to a more acid-labile structure.
328 Certainly, the core ferrihydrite is smaller and less crystalline
329 and has larger lattice spacings in the tartrate-modified
330 material (Figures 2 and 4). Additionally, our data are also
331 consistent with ligand bonding, between the tartrate, with its
332 moderate affinity for iron (log Keff = 6.49 at pH 3.54,
333 20 °C),48,49 and the surface of the ferrihydrite nanoparticles,
334so inhibiting further crystallization and growth39 and
335allowing nano-dispersion in aquated systems (Figure 1).
336Bioavailability
337Therapeutic supplementation with oral Fe(II) salts (e.g.
338ferrous sulphate) induces significant gastrointestinal side
339effects in ~30% of subjects affecting compliance and thus
340effectiveness.50,51 This issue is considered, mostly to relate to
341iron redox cycling in the gut lumen leading to the generation
342of reactive oxygen species.52 Iron (III) salts are less prone to
343the initiation of redox cycling in this environment but are
344insoluble at intestinal pH and thus are poorly absorbed.53 Iron
345(III) chelates overcome the solubility issue but are expensive
346compared to salts and still undergo reduction at the mucosal
347surface, probably via duodenal cytochrome B.54 Here we
348show that when given by oral gavage to mice, tartrate-
349modified ferrihydrite is absorbed as efficiently as the Fe(III)
350chelate, ferric nitrilotriacetate (Fe(III)NTA) (Figure 5, A).
351However, when the lumen of the gut was first flooded with
352ferrozine, an Fe(II) chelator that traps the luminal/mucosal
353surface-reduced iron,40 there was no impact on absorption of
354the tartrate-modified ferrihydrite, whereas Fe(III)NTA absorp-
355tion was almost completely inhibited, confirming Fe(III)NTA
356requirement for reduction prior to uptake, and in contrary to
357that of the modified ferrihydrite (Figure 5, A).
Figure 2. Structural characterization of the ferrihydrite. (A-D), High-angle annular dark-field, aberration-corrected, scanning transmission electron microscopy
(HAADF-STEM) images of tartrate-modified ferrihydrite in tryptophan (A, B) or adipate buffer (C), and of synthetic (unmodified) ferrihydrite (D). Scale bars
are 50 nm (A and C) or 2 nm (B and D). (E) X-ray diffraction patterns of synthetic ferrihydrite (black) and tartrate-modified ferrihydrite (red). Both patterns
have peaks characteristic of ferrihydrite, with the synthetic ferrihydrite peaks centred at 35° and 62° 2θ (2.6 Å and 1.5 Å, respectively) and the tartrate-modified
ferrihydrite peaks centered at 33° and 61° 2θ (2.7 Å and 1.5 Å, respectively), indicating expansion of the ferrihydrite lattice. Sodium tartrate is shown in green.
Synthetic ferrihydrite was precipitated from an Fe(III) chloride solution and tartrate-modified ferrihydrite from an Fe(III) chloride solution in the presence of
tartrate and tryptophan buffer (Fe/tartrate/tryptophan = 1:0.5:0.375). Excess ligand and buffer were removed from the modified material by ultrafiltration and
washing prior to drying as described in Methods.
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358 Finally, in iron-deficient anemic rats, tartrate-modified
359 ferrihydrite, added to a standard diet at 30 mg Fe/kgdiet, was
360 able to restore hemoglobin levels over 2 weeks, in line with that
361 of the gold standard ferrous sulphate (Figure 5, B). Synthetic
362 ferrihydrite, added to the diet, had no impact on hemoglobin
363 levels added to the same diet, at the same dose (Figure 5, B).
364 There was no significant difference in the body weights of the
365 animals on the tartrate-modified ferrihydrite supplemented diet
366 in comparison with those on the diet supplemented with ferrous
367 sulphate (Supplementary Table S1).
368 Discussion
369 Co-precipitation of metal ion hydroxides and organic
370 moieties to form metal oxo-hydroxides with a degree of
371 modification is well established. Typically this involves organic
372 adsorption onto the freshly formed oxo-hydroxide nanoparticles
373 which, for small anions or ligands, may enhance the formation of
374 a meta-stable, crystalline phase.55 For large molecules, such as
375 polymeric sugars, the surface coat acts to prevent secondary
376 agglomeration and aggregation, a property that has found
377 beneficial use in the production of both intravenous and oral
378 therapeutic iron preparations.56-60 Overall, however, in such
379 studies the primary particle (crystallite) of the metal oxo-
380 hydroxide appears pure in its internal structure. In contrast, here
381 we demonstrate that the polymeric, evolving primary particle of
382 ferrihydrite, can be rendered impure or “doped” with a low-
383 molecular-weight organic acid under specific conditions of co-
384 precipitation. For tartrate the spacing between carboxyl and OH
385 pairs that Fe ions might bind to during complexation in solution
386 is similar to the distance between Fe atoms in partially ordered
387 ferrihydrite.39 This might enable the organic acid to become
388 trapped in, as well as adsorbed on, precipitating ferrihydrite
389particles. Certainly, if hydrolysis proceeds too rapidly the
390organic acid ligand fails to be incorporated within the evolving
391ferrihydrite particles and, instead, is simply adsorbed onto the
392primary particles. At the other extreme, excessive concentration
393of ligand may inhibit sufficient hydrolysis of iron. However, at
394appropriate ratios of Fe/ligand/OH–, ligand-modified ferrihy-
395drite can be achieved, the properties of which differ substantially
396to the pure synthetic oxo-hydroxides due to marked changes in
397crystallinity, surface charge and stability.
398Our data are consistent with the recent studies of Eusterhues
399et al.61 who demonstrated that organic ligands may indeed
400modify, through inclusion, and disruption of iron octahedral
401cross-linking, the inter-atomic bond distances (d-spacings)
402and particle size of ferrihydrite. More recently, Mikutta62 has
403shown, with similar iron/ligand co-precipitation studies, that
404hydroxyl-benzoic acids may trigger the formation of small
405ferrihydrite nanoparticles with increased structural strain, but
406without altered d-spacing, in equilibrium with a fraction of
407lower-molecular-weight Fe(III) hydroxybenzoate complexes. In
408our system, however, the ligand-induced strain is sufficient to
409alter d-spacing (Figure 2). Furthermore, infrared analysis of
410ultrafiltered and washed material, obtained following repeated
411centrifugation steps, demonstrates co-association of ferrihydrite
412and bound tartrate but not buffer, again consistent with inclusion
413of tartrate in the ferrihydrite particles (Figure 3). Taken together
414our studies indicate that the active material reported herein is a
415ligand-modified form of ferrihydrite and not simply a mixture of
416small ferrihydrite particles and low-molecular-weight iron
417complexes. Indeed, dissolution studies indicate that all of the
418iron, and not just a labile fraction, is rendered soluble under
419lysosomal conditions (Figure 1, C). Secondly, ferrozine fails,
420entirely, to block intestinal uptake of the iron from tartrate-
421modified ferrihydrite (Figure 5, A). This again confirms that
422there is no labile Fe(III) fraction associated with the tartrate-
423modified ferrihydrite. Ferrozine is an Fe(II) chelator that has
424been well shown, both in vivo and in vitro, to markedly inhibit
425iron absorption from soluble Fe(III) complexes because these
426have an absolute requirement for reduction prior to
427absorption.40,63-66 Ferrozine traps the reduced iron (i.e. Fe(II))
428and prevents iron absorption but no such effect was seen here
429with tartrate-modified ferrihydrite. Thirdly, our recent cellular
430studies with electron microscopy and inhibition of cellular
431endocytosis, demonstrate significant intestinal cell uptake of
432whole nanoparticles.67
433The aims of this work were not to mimic the ferrihydrite-like
434core of ferritin in appearance or molecular detail but, rather, in
435terms of its functional properties that allow for iron bioavail-
436ability following ingestion by humans: namely, nanoparticle
437dispersion and an enhanced rate of acid-induced dissolution
438(and, presumably, chelator-induced dissolution). Phosphate, for
439example, which is clearly involved in interactions between the
440ferritin protein and its ferrihydrite-like core, probably contributes
441to core instability28,68 and can certainly alter the structure of
442ferrihydrite following co-precipitation and hydrothermal
443annealing.69 However, in our work, additional phosphate ions
444provided no further effect over tartrate alone in destabilizing
445synthetic ferrihydrite and, when used instead of organic acid
446ligand, phosphate was ineffective (data not shown). The
Figure 3. Fourier transform infrared (FTIR) spectroscopy of the ferrihydrite.
Synthetic (unmodified) ferrihydrite is shown in black, tryptophan in blue,
sodium tartrate in green and the tartrate-modified ferrihydrite is in red.
Unique tartrate but no tryptophan signatures are revealed in the modified
material. Synthetic and tartrate-modified ferrihydrite were prepared as per
Figure 2.
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447 additional factor of the protein shell in ferritin, as opposed to the
448 protein-free structures reported herein, may explain differing
449 phosphate sensitivities. In fact, the ligand-destabilized synthetic
450 ferrihydrite of this report may even better mimic dietary Fe(III)
451 that is dissolved under acidic, gastric conditions but then re-
452 precipitates under the much less acidic intestinal conditions:
453 endogenous ligands abound in the gastrointestinal lumen and
454 soluble mucin (once referred to as gastroferrin)70 maintains
455 the ferrihydrite nano-disperse.71 It is noteworthy that, system-
456 ically, the lysosome is used almost exclusively as the safe
457 environment for macromolecular iron turnover (e.g. cycling and
458 re-cycling of hemoglobin, Fe transferrin and ferritin) so it is not
459 inconceivable that nanoparticulate iron is also acquired by the
460 gut through intestinal endocytosis and then dissolved by
461 lysosomal acid and ligands.31,72
462 In the pursuit of novel, safe iron fortificants, Hilty et al.73 also
463 demonstrated that nano sized Fe(III)-based particles are more
464 bioavailable than bulk forms and are handled safely by the gut
465 without contributing to abnormal tissue loading, although these
466 authors regarded slow-release, gastric acid dissolution as an
467 explanation for bioavailability of their Fe(III) nanomaterials.
468 Whether dissolved in the gastric acid environment or the
469 intestinal enterocyte lysosome, we concur with Hilty et al.73
470 that labile forms of nanosized Fe(III) would join the common
471 (dietary) iron pool before basolateral export from the enterocyte,
472 ensuring normal homeostatic control of these forms of iron.
473 Moreover, for these nanomaterials the residual unabsorbed
474 Fe(III) should transit the remaining gastrointestinal tract in a
475relatively safe, non-redox active form whether it be as the
476original nanostructure or re-precipitated following gastric
477emptying. Unlike previously reported nano Fe(III) materials,
478produced by flame pyrolysis42,73 and with organoleptic
479properties suitable for fortificationa, our approach focuses on
480cheap, GRAS reagents and facile synthesis to enable inexpensive
481but safe and effective supplementationa which, as the World
482Health Organisation has noted, is especially required in
483developing and underdeveloped countries.1
484Overall, the ligand-modified ferrihydrite materials reported
485herein are noteworthy for their very small primary particle size
486(b5 nm) and enlarged lattice (circa 2.7 Å for the main Bragg
487peak) compared to synthetic ferrihydrite (2.6 Å). These findings
488therefore suggest that with appropriate buffers and Fe(III)/ligand/
489OH– ratios, conditions can be achieved for ligand inclusion into
490the developing ferrihydrite particles, retarding both growth and
491crystallization, and favoring stabilization of the cross-linked
492polymeric structure. Such materials could have beneficial
493application in one key global health priority, namely the
494prevention and treatment of iron deficiency anemia without
495side effect-inducing redox cycling in the gastrointestinal tract.
a Iron fortificants are added Q4to foods whereas iron supplements are taken
as oral tablets or capsules and typically at higher iron doses than for
fortificants. The materials reported herein are suitable as supplements due to
cheap manufacturing costs but lack the organoleptic properties (typically are
too dark in color) for fortificants.
Figure 4. Electron microscopy-based characterization of tartrate-modified ferrihydrite (red) against synthetic ferrihydrite (black). (A) Background-stripped
electron energy-loss spectra (EELS) for the combined C K-edges (285 eV), Ca L2,3-edges (346 eV), O K-edges (530 eV) and Fe L2,3-edges (709.5 eV)
normalized to the continuum intensity post the Fe L2,3-edges. (B) individual background-stripped Fe L2,3-edges. The unaltered shape of the Fe L2,3-edges
indicates that the Fe−(O, OH)6 octahedra remain relatively unchanged after tartrate modification: i.e. the material remains Fe(III). (C and D) Bright-field
transmission electron microscopy (TEM) images of synthetic ferrihydrite (C) and tartrate-modified ferrihydrite (D) agglomerates suspended over holes in the
TEM support film (see supplementary methods for details of specimen preparation). Diffraction contrast from individual crystallites produces dark regions in the
images, the size of which confirms the reduced crystallite size of the modified material. Synthetic ferrihydrite was precipitated from an Fe(III) chloride solution
and tartrate-modified ferrihydrite from an Fe(III) chloride solution in the presence of tartrate and adipate buffer (Fe/tartrate/adipate = 1:0.5:0.5).
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